DALLAS, December 19, 2011 /PRNewswire/ --
The "Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, Europe, and Japan.
Browse market data tables and in-depth TOC on Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020).
Early buyers will receive 10% customization on reports.
Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body from infections caused by bacteria. Acute myeloid leukemia is divided into childhood acute myeloid leukemia and adult acute myeloid leukemia.
Acute myeloid leukemia has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15-70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.
The acute myeloid leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html ] in G8 countries was valued at $216 million in 2010 and is expected to grow at a CAGR of 28.40% from 2015 to 2020. The market was dominated by AVD regimen in 2010. AVD regimen accounted for the largest share; i.e. 54.08% of the acute myeloid leukemia therapeutics market in G8 Countries in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cytarabine drug and Quizartinib molecule, with sales amounting to $698 million, $285 million, and $234 million respectively.
According to WHO, acute myeloid leukemia is expected to be more prominent in the developed world due to genetic and environmental factor, and radiation exposure is the primary cause of all the types of acute myeloid leukemia. Global incidence of acute myeloid leukemia was 49,539 in 2008 with the developing countries. Total 62,226 new cases were recorded in 2010 with 95,211 and 129,837 as the predicted new cases for 2015 and 2020.
The U.S. dominates the leukemia drug market in North America with a 90.19% share; whereas Germany dominates the market of Europe with 35.04% share.
The major players in the market include Ambit Biosciences Corporation (U.S.), Celgene Corporation (U.S.), Cephalon Inc. (U.S.), Clavis Pharma ASA (Norway), Eisai Co. Ltd (Japan), Genzyme Corporation (U.S.), and Sunesis Pharmaceuticals Inc. (U.S.).
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals [ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ], semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.
7557 Rambler Road,
Suite 727, Dallas, TX 75231
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/